CR20230531A - Composiciones de anticuerpos anti-tslp y usos de las mismas - Google Patents

Composiciones de anticuerpos anti-tslp y usos de las mismas

Info

Publication number
CR20230531A
CR20230531A CR20230531A CR20230531A CR20230531A CR 20230531 A CR20230531 A CR 20230531A CR 20230531 A CR20230531 A CR 20230531A CR 20230531 A CR20230531 A CR 20230531A CR 20230531 A CR20230531 A CR 20230531A
Authority
CR
Costa Rica
Prior art keywords
antibody compositions
tslp antibody
tslp
compositions
antibody
Prior art date
Application number
CR20230531A
Other languages
English (en)
Inventor
Alla Polozova
Kelly Fitzpatrick
Dong Xiang
Marisa Joubert
Hao Zhang
Kristin Abrams
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR20230531A publication Critical patent/CR20230531A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<strong>La presente solicitud se refiere, en general, a composiciones que comprenden el anticuerpo anti-TSLP tezepelumab y derivados del mismo que tienen atributos de calidad del anticuerpo.</strong><br /> <br />
CR20230531A 2021-04-23 2022-04-22 Composiciones de anticuerpos anti-tslp y usos de las mismas CR20230531A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163178938P 2021-04-23 2021-04-23
PCT/US2022/025994 WO2022226339A1 (en) 2021-04-23 2022-04-22 Anti-tslp antibody compositions and uses thereof

Publications (1)

Publication Number Publication Date
CR20230531A true CR20230531A (es) 2024-01-08

Family

ID=81597810

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230531A CR20230531A (es) 2021-04-23 2022-04-22 Composiciones de anticuerpos anti-tslp y usos de las mismas

Country Status (18)

Country Link
US (1) US20240190951A1 (es)
EP (1) EP4326766A1 (es)
JP (1) JP2024517418A (es)
KR (1) KR20240000537A (es)
CN (1) CN117203233A (es)
AR (1) AR125408A1 (es)
AU (1) AU2022262421A1 (es)
BR (1) BR112023021867A2 (es)
CA (1) CA3216655A1 (es)
CL (1) CL2023003155A1 (es)
CO (1) CO2023014181A2 (es)
CR (1) CR20230531A (es)
IL (1) IL307540A (es)
MX (1) MX2023012363A (es)
PE (1) PE20240068A1 (es)
TW (1) TW202308690A (es)
UY (1) UY39736A (es)
WO (1) WO2022226339A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2024163978A2 (en) 2023-02-02 2024-08-08 Medimmune, Llc Treatment of chronic rhinosinusitis with anti-tslp antibody

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
AT510032B1 (de) 2010-11-30 2012-01-15 Steiner Erwin Ing Montageeinrichtung für fassadenelemente
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
WO2014031718A1 (en) * 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
BR112016017606A2 (pt) 2014-01-29 2017-10-10 Amgen Inc superexpressão de reguladores de via de n-glicosilação para modular a glicosilação de proteínas recombinantes
AR103891A1 (es) * 2015-03-11 2017-06-14 Glaxosmithkline Ip Dev Ltd Proteínas de unión a tslp, ácido nucleico aislado que la codifica, vector y célula hospedadora que lo comprenden, método para producir dicha proteína, su uso para fabricar un medicamento, composición farmacéutica y kit que la comprenden
JOP20190243A1 (ar) 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
IL271499B1 (en) * 2017-08-01 2024-08-01 Amgen Inc Systems and methods for real-time polypeptide sample preparation for mass spectrometry analysis
CN111225696B (zh) 2017-11-10 2023-07-18 安进公司 用于药物递送装置的柱塞
JP2021516672A (ja) 2018-03-13 2021-07-08 アムジエン・インコーポレーテツド 質量分光測定分析のためのトリプシン耐性ポリペプチドを調製するための方法
KR20210076935A (ko) 2018-10-15 2021-06-24 암젠 인크 댐핑 메커니즘을 갖는 약물 전달 장치
SG11202101824VA (en) 2018-10-15 2021-03-30 Amgen Inc Platform assembly process for drug delivery device
EP3963589A4 (en) 2019-04-30 2023-01-25 Amgen Inc. DATA-DRIVEN PREDICTIVE MODELING FOR CELL LINE SELECTION IN BIOPHARMACEUTICAL PRODUCTION
JP2022535042A (ja) 2019-06-05 2022-08-04 アムジエン・インコーポレーテツド 治療用タンパク質の属性を特定する方法

Also Published As

Publication number Publication date
CL2023003155A1 (es) 2024-04-19
WO2022226339A9 (en) 2023-08-24
CA3216655A1 (en) 2022-10-27
PE20240068A1 (es) 2024-01-11
CN117203233A (zh) 2023-12-08
CO2023014181A2 (es) 2023-10-30
MX2023012363A (es) 2023-11-01
BR112023021867A2 (pt) 2023-12-19
UY39736A (es) 2022-10-31
US20240190951A1 (en) 2024-06-13
EP4326766A1 (en) 2024-02-28
WO2022226339A1 (en) 2022-10-27
IL307540A (en) 2023-12-01
AR125408A1 (es) 2023-07-12
JP2024517418A (ja) 2024-04-22
AU2022262421A1 (en) 2023-10-19
KR20240000537A (ko) 2024-01-02
TW202308690A (zh) 2023-03-01

Similar Documents

Publication Publication Date Title
CR20230531A (es) Composiciones de anticuerpos anti-tslp y usos de las mismas
AU2016320806A8 (en) Stable inoculant compositions and methods for producing same
EP4233843A3 (en) Antibody compositions
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
MXPA05011522A (es) Derivados de 2-acilamino-4-feniltiazol, metodo para su preparacion y su aplicacion en terapeutica.
MX2020013421A (es) Composiciones de dióxido de silicio de carbono poroso biogénico, métodos de elaboracion y uso de estas.
MY190627A (en) Anti-vegf protein compositions and methods for producing the same
WO2022226342A3 (en) Modified anti-tslp antibodies
MX2021015846A (es) Derivados de antraciclina.
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
MX2021005956A (es) Composiciones biologicas secas y metodos de las mismas.
MX2021008983A (es) Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos.
MX2022007799A (es) Hojas expansibles activadas por tension.
WO2020235974A3 (ko) 단일염기 치환 단백질 및 이를 포함하는 조성물
WO2021076574A3 (en) Fn3 domain-sirna conjugates and uses thereof
MX2023014154A (es) Anticuerpos anti-ccr8.
MX2022013840A (es) Polipéptidos de unión a pd-1 canina y usos de los mismos.
MX2023009724A (es) Sustitucion de amoniaco en productos para alterar el cabello.
IL310535A (en) Anti-GDF15 antibodies, compositions and uses thereof
MX2023001160A (es) Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo.
WO2022067233A3 (en) Canine antibody variants
WO2022238590A3 (en) Piroctone particles for use in cosmetic compositions
WO2020123070A3 (en) Emm-41 composition, methods of making and uses thereof
MX2024002913A (es) Anticuerpos anti-siglec-6 y metodos de uso de los mismos.
MX2023007302A (es) Anticuerpos contra la integrina alfa 11 beta 1.